Mannkind (MNKD) Capital Expenditures Growth (1y) (2011 - 2026)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capex Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 227.76% |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 0.57% |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 143.40% |
| 10 | Mannkind | 1.09 Bn | 956.66 Mn | 82.66 Mn | -19.09% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -19.09% |
| Dec 31, 2025 | -102.51% |
| Sep 30, 2025 | 84.03% |
| Jun 30, 2025 | -69.92% |
| Mar 31, 2025 | -80.20% |
| Dec 31, 2024 | 1,127.16% |
| Sep 30, 2024 | 82.84% |
| Jun 30, 2024 | -83.67% |
| Mar 31, 2024 | -31.62% |
| Dec 31, 2023 | -112.98% |
| Sep 30, 2023 | -2,775.79% |
| Jun 30, 2023 | 902.47% |
| Mar 31, 2023 | -51.78% |
| Dec 31, 2022 | 222.83% |
| Sep 30, 2022 | -115.49% |
| Jun 30, 2022 | -1,469.08% |
| Mar 31, 2022 | 418.03% |
| Dec 31, 2021 | -1,108.45% |
| Sep 30, 2021 | 127,225.00% |
| Jun 30, 2021 | -22.76% |
| Mar 31, 2021 | 2,950.00% |
| Dec 31, 2020 | -78.96% |
| Sep 30, 2020 | 100.68% |
| Jun 30, 2020 | -48.56% |
| Mar 31, 2020 | -88.10% |
| Mar 31, 2016 | -72.78% |
| Dec 31, 2015 | -93.63% |
| Sep 30, 2015 | -86.99% |
| Jun 30, 2015 | -45.10% |
| Mar 31, 2015 | 198.30% |
| Dec 31, 2014 | -19.51% |
| Sep 30, 2014 | 4,016.09% |
| Jun 30, 2014 | 6,156.06% |
| Mar 31, 2014 | -3.43% |
| Dec 31, 2013 | 9,386.15% |
| Sep 30, 2013 | 85.48% |
| Jun 30, 2013 | 5.60% |
| Mar 31, 2013 | 351.70% |
| Dec 31, 2012 | -58.06% |
| Sep 30, 2012 | -79.12% |
| Jun 30, 2012 | -96.96% |
| Mar 31, 2012 | -83.79% |
| Dec 31, 2011 | -96.06% |
| Sep 30, 2011 | -61.80% |